

Imugene Extraordinary General Meeting Call Details

SYDNEY, Australia, 11 November 2019: Imugene Limited (ASX:IMU), an immuno-oncology company invites investors unable to attend the Extraordinary General Meeting (EGM) to participate via teleconference.

The EGM is scheduled for 10:00 am (Melbourne time) on Monday 18th November at Level 3, 62 Lygon Street, Carlton, Victoria, Australia.

For those wishing to dial into the call, please register for the call through the following link:

<https://s1.c-conf.com/diamondpass/Imugene-10002810-invite.html>

Alternatively at the time of the call dial your respective local number below and provide the conference ID 10002810 to the operator:

Australia dial in:	1800 908 299
US dial in:	+1 855 624 0077
All other locations dial:	+61 2 9007 8048

For those eligible to vote on the EGM resolutions, the company wish to remind shareholders that the proxy voting instructions must be received by no later than 10:00 am (Melbourne time) on Saturday 16th November 2019.

The EGM proxy voting instructions can be completed online through the following link:

<https://investor.automic.com.au/#/loginsah>

For further information please contact:

Contact:

Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](#)
Like us on Facebook [@Imugene](#)
Connect with us on LinkedIn [@Imugene Limited](#)

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.